Infección por VIH y desarrollo de fenómenos autoinmunes
Palabras clave:
INFECCIONES POR VIH, ENFERMEDADES AUTOINMUNES
Resumen
La etiología de las enfermedades autoinmunes sistémicas permanece aún desconocida. Se ha invocado a los retrovirus humanos como factores desencadenantes de las mismas. La infección por virus de la inmunodeficiencia humana y el síndrome inflamatorio de reconstitución inmune se han vinculado al desarrollo de síndrome antifosfolipídico, lupus eritematoso sistémico, síndrome de Sjögren y vasculitis sistémicas, entre otras. Presentamos dos casos clínicos cuyo nexo común fue la presencia de manifestaciones autoinmunes en el contexto de la infección por el virus de la inmunodeficiencia humana.
Citas
(1) Douvas A, Takehana Y, Ehresmann G, Chernyovskiy T, Daar ES. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune in patients with mixed connective tissue disease. AIDS Res Hum Retroviruses 1996; 12(16): 1509-17.
(2) Brancato L, Itescu S, Skovron ML, Solomon G, Winchester R. Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter’s syndrome and related disorders associated with HIV infection. Rheumatol Int 1989; 9(3-5): 137-41.
(3) Medina-Rodriguez F, Guzman C, Jara LJ, Hermida C, Alboukrek D, Cervera H, et al. Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: a study of 2 populations with similar risk factors. J Rheumatol 1993; 20(11): 1880-4.
(4) Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256(4): 491-3.
(5) de Clerck LS, Couttenye MM, de Broe ME, Stevens WJ. Acquired immunodeficiency syndrome mimicking Sjögren’s syndrome and systemic lupus erythematosus. Arthritis Rheum 1988; 31(2): 272-5.
(6) Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005; 35(3): 166-74.
(7) Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295-306. .
(8) Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Antiphospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons phospholipids specificity, avidity and reactivity with beta 2-GPI. J Autoimmun 1999; 13(3): 347-55.
(9) Cervera R, Asherson RA, Acevedo ML, Gómez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63(10): 1312-7.
(10) Awodu OA, Olayemi EE, Bazuaye GN, Onunu AN. Lupus anticoagulant in human immunodeficiency virus-infected patients on highly active antiretroviral therapy. Indian J Pathol Microbiol 2010; 53(1):47-9. Disponible en: http://www.ijpmonline.org/article.asp?issn=0377-4929; year=2010;volume=53;issue=1;spage=47;epage=49;aulast=Awodu. Consulta: 16 abril 2010.
(11) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9):1725.
(12) Sekigawa I, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. Retroviruses and autoimmunity. Int Med 2001; 40(2): 80-6.
(13) Povolotsky J, Polsky B, Laurence J, Jindal R, Rozon-Solomon M, Burrows L. Withdrawal of conclusion: false positive tests for HIV in a woman with lupus. N Engl J Med 1994; 331(13): 881-2.
(14) Kulthanan K, Jiamton S, Omcharoen V, Linpiyawan R, Ruangpeerakul J, Sivayathorn A. Autoimmune and rheumatic manifestations and antinuclear antibody study in HIV-infected Thai patients. Int J Dermatol 2002; 41(7): 417-22.
(15) Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity 1994; 18(3): 205-11.
(2) Brancato L, Itescu S, Skovron ML, Solomon G, Winchester R. Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter’s syndrome and related disorders associated with HIV infection. Rheumatol Int 1989; 9(3-5): 137-41.
(3) Medina-Rodriguez F, Guzman C, Jara LJ, Hermida C, Alboukrek D, Cervera H, et al. Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: a study of 2 populations with similar risk factors. J Rheumatol 1993; 20(11): 1880-4.
(4) Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256(4): 491-3.
(5) de Clerck LS, Couttenye MM, de Broe ME, Stevens WJ. Acquired immunodeficiency syndrome mimicking Sjögren’s syndrome and systemic lupus erythematosus. Arthritis Rheum 1988; 31(2): 272-5.
(6) Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005; 35(3): 166-74.
(7) Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295-306. .
(8) Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Antiphospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons phospholipids specificity, avidity and reactivity with beta 2-GPI. J Autoimmun 1999; 13(3): 347-55.
(9) Cervera R, Asherson RA, Acevedo ML, Gómez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63(10): 1312-7.
(10) Awodu OA, Olayemi EE, Bazuaye GN, Onunu AN. Lupus anticoagulant in human immunodeficiency virus-infected patients on highly active antiretroviral therapy. Indian J Pathol Microbiol 2010; 53(1):47-9. Disponible en: http://www.ijpmonline.org/article.asp?issn=0377-4929; year=2010;volume=53;issue=1;spage=47;epage=49;aulast=Awodu. Consulta: 16 abril 2010.
(11) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40(9):1725.
(12) Sekigawa I, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. Retroviruses and autoimmunity. Int Med 2001; 40(2): 80-6.
(13) Povolotsky J, Polsky B, Laurence J, Jindal R, Rozon-Solomon M, Burrows L. Withdrawal of conclusion: false positive tests for HIV in a woman with lupus. N Engl J Med 1994; 331(13): 881-2.
(14) Kulthanan K, Jiamton S, Omcharoen V, Linpiyawan R, Ruangpeerakul J, Sivayathorn A. Autoimmune and rheumatic manifestations and antinuclear antibody study in HIV-infected Thai patients. Int J Dermatol 2002; 41(7): 417-22.
(15) Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity 1994; 18(3): 205-11.
Publicado
2010-09-30
Cómo citar
1.
Silvariño R, Cabrera S, Méndez E, Savio E. Infección por VIH y desarrollo de fenómenos autoinmunes. Rev. Méd. Urug. [Internet]. 30 de septiembre de 2010 [citado 18 de mayo de 2024];26(3):161-7. Disponible en: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/421
Sección
Casos Clínicos
